Clinical Trials Logo

Filter by:
NCT ID: NCT05661656 Not yet recruiting - Breast Cancer Clinical Trials

Catheter Guided Chemo-infusion in Breast Cancer

Start date: April 2023
Phase: N/A
Study type: Interventional

In the present prospective study, we will analyze the outcome of image-guided delivery of intra-arterially infused chemotherapeutic drugs for patients with breast cancer in III, IV stages.

NCT ID: NCT05665296 Not yet recruiting - Clinical trials for Upper Crossed Syndrome

Effect of Cervicothoracic Mobilization on Upper Crossed Syndrome

Start date: April 2023
Phase: N/A
Study type: Interventional

PURPOSE: To investigate the effect of cervicothoracic mobilization on Craniovertebral angle (CVA), sagittal shoulder angle (SSA), kyphotic angle and pain intensity level in upper crossed syndrome.

NCT ID: NCT05676788 Not yet recruiting - Lung Neoplasm Clinical Trials

HSI for Intersegmental Plane Identification During Sublobar Pulmonary Resections

HYPER-Seg
Start date: April 2023
Phase: N/A
Study type: Interventional

The purpose of this study is the identification of the intersegmental plane and navigation during sublobar pulmonary resections in lung cancer using Hyperspectral Imaging, the comparison with ICG fluorescence intersegmental plane identification, and the establishment of automatic intersegmental plane navigation using machine learning strategies for intraoperative navigation.

NCT ID: NCT05681364 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Prediction of Pulmonary Rehabilitation Outcomes in Patients With Chronic Respiratory Disease Based on Metabolomics: a Prospective Cohort Study

Start date: April 2023
Phase:
Study type: Observational

To comprehensively evaluate the pulmonary rehabilitation (PR) outcomes of patients with chronic respiratory disease (CRD), and to screen biomarkers for predicting different PR outcomes of patients with CRD using metabolomics methods, and to build a prediction model.

NCT ID: NCT05700656 Not yet recruiting - Clinical trials for Colorectal Cancer Metastatic

Galunisertib Combined With Capecitabine in Advanced CRC With PM

Start date: April 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a two-center open-label non-randomized proof of principle study consisting of a dose-finding part (phase I) and phase II study with Simon two-stage design investigating the anti-tumor activity of the combination of capecitabine and galunisertib in patients with colorectal cancer with peritoneal metastases.

NCT ID: NCT05714397 Not yet recruiting - Clinical trials for Anterior Knee Pain Syndrome

Effectiveness of Cingal™ for Improving Pain Scores and Function in Anterior Knee Pain

Start date: April 2023
Phase: N/A
Study type: Interventional

Anterior Knee Pain (AKP) is a common condition that can be challenging to treat effectively. The main goal of treatment regimens is to improve the function of the knee. However, treatment can be challenging due to the knee pain experience. Cingal™ contains hyaluronic acid (HA), which acts as a joint lubricant, and the corticosteroid triamcinolone hexacetonide (TH). Some studies have shown that Cingal™ can improve joint function and provide short-term pain relief.

NCT ID: NCT05716646 Not yet recruiting - Stroke Clinical Trials

In the Real World Study, the Efficacy and Adverse Reactions of Ticagrelor on Ischemic Cerebrovascular Disease

Start date: April 2023
Phase:
Study type: Observational

This is a forward-looking, open, one-arm, and real clinical trial world. The researchers plan to recruit at least 50 qualified patients. The main purpose of this study is to establish a population pharmacokinetic model of ticagrelor , explore the correlation between its blood concentration and the events of ischemia and the adverse effects of hemorrhage, and evaluate the effectiveness and safety of ticagrelor in the treatment of ischemic cerebrovascular disease.

NCT ID: NCT05720910 Not yet recruiting - Breast Cancer Clinical Trials

Streamlined Geriatric and Oncological Evaluation Based On IC Technology

FRONE
Start date: April 2023
Phase: N/A
Study type: Interventional

The primary objective of GERONTE STUDY is to evaluate the effectiveness of the GERONTE, ICT-based, integrated care pathway to improve patient 6-month quality of life, in France. Study design is a stepped wedge randomised controlled trial. Clusters will be participating hospitals, comprising eight investigating sites in total (Figure 2). This is a stepped wedge of cross-over type. Patients included at each "step" are different individuals. The first "step" is a reference measurement where none of the clusters will implement the intervention. The investigating sites will be randomly drawn to determine the order in which they will implement the intervention, by "steps" of two months. The primary endpoint is the Quality of Life assessed by the EORTC QLQ-C30 (version 3.0) questionnaire at 6 months after GERONTE implementation. It has 3 sub-scores that will be analysed independently, with alpha risk adjustment.

NCT ID: NCT05723705 Not yet recruiting - Liver Cancer Clinical Trials

Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)

LIVEROBOT
Start date: April 2023
Phase:
Study type: Observational

LIVEROBOT is a collaboration of high-volume liver surgical centers in Europe (≥60 liver resections per year), supported by the European-African Hepato-Pancreato-Biliary Association Education Committee (E-AHPBA), and the European Registry of Minimally Invasive Liver Surgery (E-MILS) aiming to support the step-up implementation and safety of advanced surgical expertise of robotic liver surgery (RLS) on a European basis. The LIVEROBOT training program aims to promote the safe implementation of RLS throughout Europe. The data from all patients operated on during a surgeons' participation in the training program will be prospectively gathered allowing for learning curve and outcome analyses.

NCT ID: NCT05732662 Not yet recruiting - Clinical trials for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC

Start date: April 2023
Phase: Phase 2
Study type: Interventional

The entire treatment process is divided into two phases: Phase I SBRT combined with PD-1/CTLA-4 bispecific antibody (AK104) and Phase II AK104 single-agent maintenance therapy.